Cosmetic composition containing 13-hydroxy-9(Z)-octadecenoic acid for the stimulation of hair growth

The use of 13-hydroxy-9(Z)-octadecenoic acid in a cosmetic composition stimulates hair growth and repairs hair fibers by increasing PGE2 and VEGF secretion, effectively addressing hair cycle disruptions and promoting healthier hair growth.

FR3161554A1Pending Publication Date: 2025-10-31CAUDALIE GRP LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
FR2024004467
Authority / Receiving Office
FR · FR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-04-29
Publication Date
2025-10-31

AI Technical Summary

Technical Problem

Existing cosmetic compositions do not effectively stimulate hair growth and repair hair fibers, particularly due to disruptions in the hair cycle caused by factors such as stress, hormonal changes, nutritional deficiencies, and aging, leading to issues like shortening of the anagen phase and hair thinning.

Method used

A cosmetic composition containing 13-hydroxy-9(Z)-octadecenoic acid (13-HOD) as an active ingredient, which is derived from modified vegetable oils, is used to stimulate hair growth and repair hair fibers by increasing PGE2 secretion and promoting VEGF activity.

Benefits of technology

13-HOD significantly enhances PGE2 and VEGF secretion, leading to improved hair growth and follicle development, outperforming ricinoleic acid in efficacy even at lower concentrations, and effectively addresses hair cycle disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Cosmetic composition containing 13-hydroxy-9(Z)-octadecenoic acid for stimulating hair growth. The invention relates to a cosmetic composition comprising 13-hydroxy-9(Z)-octadecenoic acid as its active ingredient. The cosmetic composition is used for stimulating hair growth and repairing the hair fiber. Figure for the abstract: Fig. 3
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Cosmetic composition containing 13-hydroxy-9(Z)-octadecenoic acid for stimulating hair growth

[0001] The present invention relates to a cosmetic composition containing 13-hydroxy-9(Z)-octadecenoic acid (hereinafter abbreviated 13-HOD) for stimulating hair growth, as well as repairing the hair fiber.

[0002] In the context of the present invention, "stimulation of hair growth" means both the stimulation of hair growth and that of beard, eyelashes or eyebrows.

[0003] The hair cycle is composed of 3 phases: the anagen phase (growth phase), the catagen phase (regression phase) and the telogen phase (resting phase).

[0004] The anagen phase corresponds to the continuous proliferation of matrix cells at the level of the hair bulb. Cellular activity is intense to ensure keratinization and thus the growth of the hair.

[0005] The catagen phase corresponds to the cessation of mitotic activity in the hair bulb. The hair bulb regresses through apoptosis and detaches from the dermal papilla. Without the dermal papilla, the hair is no longer irrigated and it grows back into the epidermis.

[0006] The telogen phase is characterized by the shedding of the hair.

[0007] Entry into a new growth cycle depends on signals from the dermal papilla that activate the bulge stem cells and allow the regeneration of the hair follicle. Since hair follicles are sensitive to many factors, the duration of the anagen phase can be shortened (and the duration of the telogen phase lengthened) by exposure to external stresses, hormonal changes, or nutritional deficiencies.

[0008] The hair cycle is regulated by the interaction between dermal papilla cells and epithelial cells of the hair follicle. Dermal papilla cells can promote and maintain the growth and development of hair follicles by secreting various cytokines and growth factors. These cells play an important role in hair follicle regeneration and growth by maintaining the hair follicle in the anagen phase.

[0009] During the anagen phase, the hair follicle requires sufficient nutrients to allow cell division of the matrix cells. Vascular endothelial growth factor (hereinafter abbreviated as "VEGF") plays an important role in induction VEGF stimulates endothelial cell angiogenesis, the process of new blood vessel growth. Specifically, VEGF induces the proliferation of a capillary network during the anagen phase in the dermal papilla. Angiogenesis leads to improved blood flow to the hair follicle, resulting in a better supply of nutrients that promote hair growth.

[0010] Furthermore, VEGF, through binding to the vascular endothelial growth factor receptor 2 (hereafter abbreviated as "VEGFR-2"), activates the extracellular signal-regulatory kinase (ERK) pathway. This signaling pathway, following a series of intracellular phosphorylations, allows the transcription of genes responsible for the proliferation of dermal papilla cells.

[0011] Thus, the cells of the dermal papilla produce VEGF, which will stimulate their proliferation and migration.

[0012] Consequently, VEGF regulates hair growth through its angiogenic effect but also through the VEGFR-2 receptor expressed on dermal papilla cells.

[0013] Furthermore, prostaglandins are lipid-soluble molecules secreted into the extracellular environment that play an important role as paracrine and autocrine signaling agents.

[0014] Prostaglandin E2 (hereinafter abbreviated as "PGE2") is linked to hair growth. It is produced from prostaglandin H2 by prostaglandin E synthase. PGE2 is associated with the induction of VEGF. It thus plays a role in the induction of hair growth.

[0015] Prostaglandin D2 (hereinafter abbreviated as "PGD2") is a negative regulator of hair growth. PGD2 is produced through the enzymatic conversion of its precursor, prostaglandin H2, by prostaglandin D synthase. PGD2 is an important regulator of inflammation. One of the receptors for PGD2, the GRP44 receptor, is expressed in the outer sheath of the hair follicle. Studies have shown that high levels of PGD2 in human and animal models are associated with inhibition of hair follicle growth, and topical application of PGD2 inhibits hair growth. PGD2 stops hair growth by shortening the anagen phase through activation of the GRP44 receptor, leading to an increased proportion of follicles in the telogen phase and to hair follicle miniaturization.

[0016] Hair growth is optimal when there is an increase in PGE2 and a decrease in PGD2 within the hair follicle.

[0017] It is known that the hair growth cycle can be disrupted by various factors, including stress, genetics, vitamin deficiencies, hormones, fatigue, medication, and insufficient blood supply to the scalp. These factors will lead to changes in the duration of each phase of hair growth, notably a shortening of the anagen phase. Continuous exposure to pollution and seasonal changes can also cause premature entry into the telogen phase of the hair.

[0018] Slow hair growth can also result from poor maintenance with inappropriate care and frequent use of heat during styling. Finally, eyelashes can be prone to premature loss during vigorous makeup removal or the use of waterproof mascara.

[0019] Furthermore, aging leads to a shortening of the anagen phase, hair weakening, and a loss of hair quality through the cessation of mitotic activity in keratinocytes and the death of stem cells. Hair loss occurs when cell signaling pathways in hair follicle cells are altered, resulting in the induction of apoptosis, changes in the hair cycle, and hair thinning.

[0020] A vegetable oil generally comprises, in mass percentages expressed in relation to the mass of said vegetable oil, between about 95% and about 99% triglycerides, the other constituents of the vegetable oil being minor.

[0021] Triglycerides are glycerides in which the three hydroxyl groups of glycerol are esterified by fatty acids, which may be identical or different. Triglycerides are thus esters derived from one molecule of glycerol and three molecules of fatty acids, or in other words, glycerol-fatty acid triesters.

[0022] Depending on the plant species from which it is derived and the extraction process, a vegetable oil is more or less rich in saturated, polyunsaturated, and monounsaturated fatty acids. The distribution between the different fatty acids gives the vegetable oil specific physical properties (for example, its texture and fluidity).

[0023] Thus, a vegetable oil comprises a mixture of fatty acids in the predominant form of triglycerides. Depending on the method of obtaining the vegetable oil, free fatty acids may be present, but in very small quantities. A vegetable oil can be obtained by mechanical extraction, in particular by pressing. It may be refined or unrefined.

[0024] Castor vegetable oil is derived from the seeds of the common castor bean plant. Ricinoleic acid (also known as "12-hydroxy-9-cis-octadecenoic acid") constitutes approximately 90% of its fatty acids, which are in the form of triglycerides. It has the following chemical structure (1):

[0025] [Chem.l] (1)

[0026] Castor oil, as well as ricinoleic acid, are known to promote hair growth.

[0027] Furthermore, patent applications WO 2021 / 209437 A1 and WO 2021 / 209442 A1 describe natural cosmetic compositions for stimulating hair growth that are free of any preservatives. These compositions include, as active ingredients, ricinoleic acid in combination with arachidonate and possibly diosgenin.

[0028] However, given consumer needs in the field of cosmetics, there is still a real interest in developing new cosmetic compositions that stimulate hair growth and / or repair the hair fiber, and this with very effective results in order to effectively address the hair cycle disorders mentioned above.

[0029] The inventors have discovered, quite surprisingly, that a cosmetic composition containing 13-HOD as its active ingredient fully satisfies all these objectives. As will be detailed in the experimental section below, the inventors have demonstrated all the beneficial effects of 13-HOD on stimulating hair growth and repairing the hair fiber.

[0030] The invention thus relates to a cosmetic composition which is characterized in that it comprises 13-HOD as an active ingredient.

[0031] 13-HOD has the following chemical structure (2):

[0032] [Chem.2] (2)

[0033] 13-HOD is a hydroxylated derivative of linoleic acid, which is a fatty acid. 13-HOD is therefore a hydroxylated fatty acid.

[0034] Linoleic acid has the following chemical structure (3):

[0035] [Chem.3] g (3)

[0036] Linoleic acid is present, in varying quantities, in many vegetable oils (for example grape seed or sunflower oil), mainly in the form of triglycerides and therefore very little in the form of free fatty acids.

[0037] Unlike linoleic acid, vegetable oils do not naturally contain 13-HOD. In other words, there is no naturally occurring 13-HOD.

[0038] 13-HOD is known for its use as an intermediate in the preparation of lactones, which are chemical compounds used in a wide variety of fields of application such as food, polymers, agriculture and especially in cosmetics and perfumery.

[0039] Therefore, synthetic routes of 13-HOD are perfectly known and mastered by those skilled in the art, given that they are notably implemented during lactone preparation processes.

[0040] For example, 13-HOD can be obtained from pure linoleic acid. In this regard, US patent 11,499,171 B2 describes a biocatalytic synthesis route of 13-HOD from pure linoleic acid and in the presence of a modified microorganism producing a protein of a defined amino acid sequence and having 13-linoleate hydratase activity.

[0041] As explained above, vegetable oils do not naturally contain 13-HOD. However, processing a natural vegetable oil can yield a modified vegetable oil containing 13-HOD.

[0042] In this regard, patent application IT 2019 / 00015713 A1 describes the following transformation steps of a vegetable oil which allow the production of a modified vegetable oil comprising 13-HOD: - the biocatalytic hydrolysis of triglycerides present in vegetable oil in order to obtain fatty acids (in particular oleic, linoleic and linolenic acid) in free form, by means of an enzyme (lipase); - hydration by bioconversion of the double bonds of the fatty acids thus released in the previous step by means of bacterial fermentation with the use of probiotic microorganisms expressing hydratase enzymes in order to transform linoleic acid into 13-HOD.

[0043] Therefore, in one embodiment of the invention, the cosmetic composition comprises at least one modified vegetable oil containing 13-HOD.

[0044] In the context of the present invention, "modified vegetable oil" means a vegetable oil that does not exist in a natural form. Indeed, as explained above, vegetable oils do not naturally contain 13-HOD.

[0045] The modified vegetable oil may comprise, in mass percentages expressed relative to the total mass of free fatty acids contained in said modified vegetable oil, at least 10%, preferably at least 20%, and even more preferably at least 40%, of 13-HOD. The modified vegetable oil may comprise, in mass percentages expressed relative to the total mass of free fatty acids contained in said modified vegetable oil, between 10% and 80%, preferably between 20% and 70%, and more preferably between 30% and 60%, of 13-HOD.

[0046] Indeed, unlike so-called "natural" vegetable oils, which, as explained above, are characterized by the fact that almost all of their fatty acids are in the form of triglycerides, modified vegetable oil can be a vegetable oil whose specific characteristic is that its fatty acids (including 13-HOD) are primarily in free form. For example, modified vegetable oil can contain between 80% and 100%, preferably between 90% and 99%, of fatty acids in free form, relative to the total mass of fatty acids it contains.

[0047] The modified vegetable oil may contain a small amount of triglycerides. For example, the modified vegetable oil may contain, as a mass percentage relative to the total mass of said modified vegetable oil, less than 20%, preferably less than 10%, and more preferably less than 5%, of triglycerides. The modified vegetable oil may also contain, as a mass percentage relative to the total mass of said modified vegetable oil, between 0.5% and 20%, preferably between 1% and 15%, and more preferably between 3% and 10%, of triglycerides.

[0048] Preferably, the modified vegetable oil may not contain glycerol or may contain traces of glycerol. The mass percentage of glycerol, expressed as a percentage of the total mass of said vegetable oil, may be at most 5%, preferably 2%. In one embodiment of the invention, said mass percentage of glycerol may be between 0.05% and 5%, preferably between 0.1% and 3%, more preferably between 0.2% and 2%.

[0049] The vegetable oil may be chosen from the group consisting of grapeseed, safflower, borage, peanut, wheat germ, corn, sunflower, blackberry, black cumin, evening primrose, pumpkin seed, hemp, cottonseed, walnut, soybean, argan, and rapeseed oils, taken alone or in mixtures thereof. These vegetable oils naturally have high linoleic acid content. Their processing, according to transformation processes perfectly within the capabilities of those skilled in the art, This allows for the production of modified vegetable oils containing 13-HOD. Preferably, the vegetable oil is grapeseed oil.

[0050] The cosmetic composition according to the invention may comprise, in mass percentages expressed in relation to the total mass of said cosmetic composition, between 0.0001% and 1%, preferably between 0.001% and 0.1%, of 13-HOD.

[0051] When the cosmetic composition includes a modified vegetable oil containing 13-HOD, the mass percentage of said modified vegetable oil, expressed in relation to the total mass of said cosmetic composition, may be between 0.0005% and 5%, preferably between 0.005% and 0.5%.

[0052] The cosmetic composition according to the invention may further comprise at least one adjuvant selected from among the adjuvants commonly used in the field of cosmetics. These may include, for example, emulsifiers, surfactants, hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, fillers, pigments or coloring matter, ultraviolet filters or pH stabilizers.

[0053] The mass percentages of these various adjuvants are those conventionally used in the field of cosmetics. For example, these mass percentages range from 0.01% to 20% relative to the total mass of said cosmetic composition.

[0054] These adjuvants, depending on their nature, can be introduced into the oily phase, into the aqueous phase or into the lipid vesicles of the cosmetic composition according to the invention.

[0055] In any event, these adjuvants, as well as their quantities, are chosen so as not to impair the desired properties of 13-HOD.

[0056] Examples of hydrophilic gelling agents include carboxyvinyl polymers, acrylic copolymers such as acrylate / alkylacrylate copolymers, polysaccharides, natural gums and clays, and examples of lipophilic gelling agents include modified clays such as bentones and hydrophobic silica.

[0057] Examples of fillers include polymethyl methacrylate microspheres, acrylate-acrylate copolymer powders, expanded powders such as hollow microspheres, and in particular, powders of natural organic materials such as starch powders, in particular corn, wheat or rice starches, crosslinked or not, such as starch powders crosslinked by octenylsuccinate anhydride, silica, metal oxides such as titanium dioxide or zinc oxide, mica, and mixtures thereof.

[0058] Examples of antioxidants include tocopherol (in other words, the aforementioned vitamin E) and its esters, in particular tocopherol acetate, acid ascorbic acid (in other words the aforementioned vitamin C) and its derivatives, in particular ascorbyl magnesium phosphate, ascorbyl glucoside and ascorbyl tetraisopalmitate, ferulic acid, serine, ellagic acid, phloretin and their mixtures.

[0059] The cosmetic composition according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a solution, a shampoo, a serum, a paste, a mask, or even a mousse. The cosmetic composition according to the invention may also be in solid form, for example, in the form of a stick.

[0060] The cosmetic composition according to the invention can be presented in all the galenic forms normally used in the field of cosmetics.

[0061] It can, for example, be in the form of an aqueous or oily solution possibly gelled, a lotion-type dispersion possibly biphasic, an emulsion obtained by dispersing a fatty phase in an aqueous phase (O / W) or conversely an aqueous phase in a fatty phase (W / O), or even a triple emulsion (W / O / W or W / O / O) or a vesicular dispersion of ionic and / or non-ionic type.

[0062] The cosmetic composition according to the invention can be prepared according to conventional methods. For example, when the cosmetic composition according to the invention is an emulsion, the mass percentage of the oil phase can be between 0.5% and 80%, and preferably between 5% and 50%, relative to the total mass of said cosmetic composition.

[0063] The oils, emulsifiers and co-emulsifiers used in the cosmetic composition according to the invention in the form of an emulsion are chosen from those classically used in the field concerned.

[0064] The mass percentage of emulsifier and co-emulsifier may be between 0.1% and 30%, preferably between 0.5% and 20%, relative to the total mass of said cosmetic composition.

[0065] Emulsifiers and co-emulsifiers can be selected from fatty acid and glycerin esters such as glyceryl stearate, sucrose esters and phospholipids.

[0066] The cosmetic composition according to the invention may further comprise at least one oil selected from vegetable oils (for example almond oil, apricot oil, liquid fraction of shea butter, avocado and soybean oil) and synthetic oils (for example isononyl isononanoate, pentaerythrityl tetraoctanoate).

[0067] The cosmetic composition according to the invention may further comprise fats selected from fatty alcohols (for example cetyl or stearyl alcohol), fatty acids (for example stearic acid) and waxes (for example camauba, ozokerite or beeswax).

[0068] The invention also relates to a non-therapeutic cosmetic process for stimulating hair growth, characterized in that it includes a step of applying the cosmetic composition according to the invention to a determined hairy area.

[0069] The defined hair area may be all or part of the scalp, chin, eyebrows, or the free edges of the eyelids on which the eyelashes are implanted. In other words, the cosmetic composition according to the invention may be applied to all or part of the scalp, chin, eyebrows, or eyelashes.

[0070] Preferably, the hairy area is the scalp.

[0071] In one embodiment of the invention, the cosmetic composition according to the invention is used to stimulate eyelash growth. Therefore, the invention also relates to a makeup composition, preferably a mascara composition, characterized in that it comprises the cosmetic composition according to the invention as described above.

[0072] The invention also relates to a non-therapeutic cosmetic use of 13-HOD to stimulate hair growth.

[0073] The invention also relates to a non-therapeutic cosmetic process for repairing hair fibers, characterized in that it includes a step of applying the cosmetic composition according to the invention to all or part of the scalp.

[0074] The invention also relates to a non-therapeutic cosmetic use of 13-HOD to repair the hair fiber.

[0075] The invention and its advantages are illustrated in the examples below.

[0076] Examples:

[0077] Presentation of compound A and oils A to C:

[0078] Compound A:

[0079] Compound A contained, in mass percentages expressed as a percentage of the total mass of said compound A: -71.8% of 13-HOD; - 28.2% linoleic acid.

[0080] This compound A was obtained from pure linoleic acid which was subjected to enzymatic biocatalysis such that 71.8% of the linoleic acid was transformed into 13-HOD.

[0081] In the modified grape seed oils A to C described below, the fatty acids were essentially in free form. Indeed, these three modified grape seed oils A to C result from the complete conversion of the triglycerides contained in the grape seed oil from which each is derived.

[0082] Oil A:

[0083] Oil A was a modified grapeseed oil which contained, in mass percentages expressed relative to the total mass of free fatty acids in said oil A: - 45.6% of 13-HOD; - 19.5% linoleic acid; - 19.1% oleic acid; - 10.6% palmitic acid; - 5.2% stearic acid.

[0084] Oil B:

[0085] Oil B was a modified grapeseed oil which contained, in mass percentages expressed relative to the total mass of free fatty acids in said oil B: - 46.9% of 13-HOD; - 12.8% linoleic acid; - 22.5% oleic acid; - 11.6% palmitic acid; - 6.2% stearic acid.

[0086] Oil C:

[0087] Oil C was a modified grapeseed oil which contained, in mass percentages expressed relative to the total mass of free fatty acids in said oil C: - 53.3% of 13-HOD; - 21.2% linoleic acid; - 15.3% oleic acid; - 6.9% palmitic acid; - 3.3% stearic acid.

[0088] Thus, in modified grape seed oils A to C, 13-HOD was the predominant fatty acid among the free fatty acids contained in said modified grape seed oils A to C.

[0089] 1 — series of experiments: effect of compound A on the secretion of PG E2 and PG D2

[0090] The following IA to IC and Control 1 tests were carried out.

[0091] In each of the IA to IC and Control 1 trials, dermal papilla cells from hair follicles were cultured in a culture medium marketed by Promocell under the trade name "Follicle Dermal Papilla Cell Growth Medium" and which was placed in a humid atmosphere containing 5% CO2 at 37°C.

[0092] AI Test:

[0093] Compound A was diluted in dimethyl sulfoxide (hereinafter abbreviated as "DMSO") to obtain a stock solution of said compound A having a concentration of said compound A of 10 mg / mL.

[0094] The stock solution of compound A was then appropriately diluted in DMSO such that: - that a dilute solution of said compound A was obtained and then added to the aforementioned culture medium, - the mass percentage of compound A expressed in relation to the mass of said culture medium was 0.0005% (i.e. 0.000359% of 13-HOD taking into account that compound A comprised 71.8% of 13-HOD).

[0095] After 48 hours of treatment of dermal papilla cells with compound A at a mass concentration of 0.0005%, the supernatants were recovered. The amounts of secreted PGE2 and PGD2 were measured by enzyme-linked immunosorbent assays (hereafter abbreviated as "ELIS A assays," which is the English acronym for Enzyme-Linked Immunosorbent Assay) and normalized by cell viability.

[0096] Test IB:

[0097] Ricinoleic acid was diluted in DMSO to obtain a ricinoleic acid stock solution with a ricinoleic acid concentration of 10 mg / mL.

[0098] The ricinoleic acid stock solution was then appropriately diluted in DMSO such that: - that a dilute solution of ricinoleic acid was obtained and then added to the aforementioned culture medium, - the mass percentage of ricinoleic acid expressed in relation to the mass of said culture medium was 0.001%.

[0099] After 48 hours of treatment of dermal papilla cells with ricinoleic acid at a mass concentration of 0.001%, the supernatants were recovered. The amounts of secreted PGE2 and PGD2 were measured by ELISA assays and normalized by cell viability.

[0100] IC Test:

[0101] Ricinoleic acid was diluted in DMSO to obtain a ricinoleic acid stock solution with a ricinoleic acid concentration of 10 mg / mL.

[0102] The ricinoleic acid stock solution was then appropriately diluted in DMSO such that: - that a dilute solution of ricinoleic acid was obtained and then added to said culture medium, - the mass percentage of ricinoleic acid expressed in relation to the mass of said culture medium was 0.002%.

[0103] After 48 hours of treatment of dermal papilla cells with ricinoleic acid at a mass concentration of 0.002%, the supernatants were recovered. The amounts of secreted PGE2 and PGD2 were measured by ELISA assays and normalized by cell viability.

[0104] Test Control 1;

[0105] Furthermore, a Control Test 1 was performed by adding no active ingredient to the culture medium in which the dermal papilla cells were cultured. After 48 hours of culture of said dermal papilla cells, the supernatants were collected. The amounts of PGE2 and PGD2 secreted were measured by ELISA assays and normalized by cell viability.

[0106] Fig. 1 is a graph representing the amounts of PGE2 and PGD2 secreted by dermal papilla cells during IA to IC trials, said amounts being expressed as percentages relative to the amounts of PGE2 and PGD2 secreted during Control Trial 1 and normalized to 100%.

[0107] As shown in the graph in [Fig. 1], a very significant amount of PGE2 was secreted during trial IA, unlike in trials IB and IC. This means that, unlike ricinoleic acid, 13-HOD induced a significant increase in PGE2 secretion, even at a concentration much lower than that of ricinoleic acid (0.000359% versus 0.001% and 0.002%).

[0108] Furthermore, in the IA trial, very little PGD2 was secreted. 13-HOD did not induce significant PGD2 secretion.

[0109] This first series of experiments demonstrates that 13-HOD is more effective than ricinoleic acid in stimulating hair follicle growth. Indeed, treatment with 13-HOD resulted in a very significant increase in PGE2 secretion and a low secretion of PGD2.

[0110] 2 — Series of experiments: Effect of compound A on VEGF secretion

[0111] The following tests 2A to 2C and Control 2 were carried out.

[0112] In each of the trials 2A to 2C and Control 2, dermal papilla cells from hair follicles were cultured in a culture medium identical to that of the first series of experiments which was placed in a humid atmosphere containing 5% CO2 at 37°C.

[0113] Test 2A:

[0114] The preparation of test 2A was identical to that of test IA detailed above.

[0115] After 48 hours of treatment of dermal papilla cells with the compound At a mass concentration of 0.0005%, the supernatants were recovered. The amount of secreted VEGF was measured using assays and normalized by cell viability.

[0116] Test 2B:

[0117] The preparation of test 2B was identical to that of test IB detailed above.

[0118] After 48 hours of treatment of dermal papilla cells with ricinoleic acid at a mass concentration of 0.001%, the supernatants were recovered. The amount of VEGF secreted was measured by ELISA assays and normalized by cell viability.

[0119] Test 2C:

[0120] The preparation of test 2C was identical to that of test IC detailed above.

[0121] After 48 hours of treatment of dermal papilla cells with ricinoleic acid at a mass concentration of 0.002%, the supernatants were recovered. The amount of VEGF secreted was measured by ELISA assays and normalized by cell viability.

[0122] Test Control 2:

[0123] In addition, a Control Test 2 was carried out by adding no active ingredient to the culture medium in which the dermal papilla cells were cultured.

[0124] After 48 hours of culture of said dermal papilla cells, the supernatants were collected. The amount of VEGF secreted was measured by ELISA assays and normalized by cell viability.

[0125] Fig. 2 is a graph representing the amount of VEGF secreted into dermal papilla cells during trials 2A to 2C, the amount of VEGF secreted being expressed as a percentage relative to the amount of VEGF secreted during Control Trial 2 and normalized to 100%.

[0126] As shown in the graph in [Fig. 2], in trial 2A, 13-HOD significantly stimulated VEGF secretion. This significant stimulation of VEGF secretion was also observed in trial 2C, namely with ricinoleic acid, but at a much higher concentration (0.002% versus 0.000359%).

[0127] 13-HOD thus has an effect on the secretion of VEGF which, as explained above, has a beneficial effect on hair growth.

[0128] 3 — series of experiments: effect of oil A on the secretion of PGE2

[0129] The following tests 3A to 3C and Control 3 were carried out.

[0130] In each of the trials 3A to 3C and Control 3, dermal papilla cells from hair follicles were cultured in a culture medium identical to that of the first series of experiments which was placed in a humid atmosphere containing 5% CO2 at 37°C.

[0131] Test 3A:

[0132] Oil A was diluted in DMSO to obtain a stock solution of said oil A having a concentration of said oil A of 10 mg / mL.

[0133] The stock solution of oil A was appropriately diluted in DMSO such that: - that a diluted solution of said oil A was obtained and then added to the aforementioned culture medium, - the mass percentage of oil A expressed in relation to the mass of said culture medium was 0.001% (i.e. 0.000456% of 13-HOD, if we consider the very small mass of unsaponifiables present in said oil A as negligible and taking into account that oil A contained essentially free fatty acids, of which 13-HOD had a mass content of 45.6%).

[0134] After 48 hours of treatment of dermal papilla cells with oil A at a mass concentration of 0.001%, the supernatants were recovered. The amounts of secreted PGE2 were measured by ELISA assays and normalized by cell viability.

[0135] Test 3B:

[0136] Oil A was diluted in DMSO to obtain a stock solution of said oil A having a concentration of said oil A of 10 mg / mL.

[0137] The stock solution of oil A was appropriately diluted in DMSO such that: - that a diluted solution of said oil A was obtained and then added to the aforementioned culture medium, - the mass percentage of oil A expressed in relation to the mass of said culture medium was 0.002% (i.e. 0.000912% of 13-HOD, if we consider the very small mass of unsaponifiables present in said oil A as negligible and taking into account that oil A contained essentially free fatty acids, of which 13-HOD had a mass content of 45.6%).

[0138] After 48 hours of treatment of dermal papilla cells with oil A at a mass concentration of 0.002%, the supernatants were recovered. The amounts of PGE2 secreted were measured by ELISA assays and normalized by cell viability.

[0139] Test 3C:

[0140] Castor oil was diluted in DMSO to obtain a stock solution of said castor oil having a concentration of said castor oil of 10 mg / mL.

[0141] The castor oil stock solution was appropriately diluted in DMSO such that: - that a diluted solution of said castor oil was obtained and then added to the aforementioned culture medium, - the mass percentage of castor oil expressed in relation to the mass of said culture medium was 0.001% (i.e. 0.0009% of ricinoleic acid taking into account that castor oil comprised 90% ricinoleic acid and if we neglect the unsaponifiables present in said castor oil).

[0142] After 48 hours of treatment of dermal papilla cells with castor oil at a mass concentration of 0.001%, the supernatants were recovered. The amounts of secreted PGE2 were measured by ELISA assays and normalized by cell viability.

[0143] Test Control 3:

[0144] Furthermore, a Control Test 3 was performed by adding no active ingredient to the culture medium in which the dermal papilla cells were cultured. After 48 hours of culture of said dermal papilla cells, the supernatants were collected. The amounts of PGE2 secreted were measured by ELISA assays.

[0145] Fig. 3 is a graph representing the amounts of PGE2 secreted by dermal papilla cells during trials 3A to 3C, said amounts expressed as percentages relative to the amount of PGE2 secreted during Control Trial 3 and normalized to 100%.

[0146] As shown in the graph in [Fig. 3], a significant amount of PGE2 was secreted during trials 3A and 3B, unlike in trial 3C. This means that, unlike castor oil which contains ricinoleic acid, oil A which contained 13-HOD induced a significant increase in PGE2 secretion, which has a beneficial effect on hair growth.

[0147] 4 — series of experiments: Effect of oil C on the expression of VEGF j.

[0148] The following tests 4A to 4C and Control 4 were carried out.

[0149] In each of the trials 4A to 4C and Control 4, dermal papilla cells from hair follicles were cultured in a culture medium identical to that of the 1st series of experiments which was placed in a humid atmosphere containing 5% CO2 at 37°C.

[0150] Test 4A:

[0151] Oil C was diluted in DMSO to obtain a stock solution of said oil C having a concentration of said oil C of 10 mg / mL.

[0152] The stock solution of oil C was appropriately diluted in DMSO such that: - that a diluted solution of said oil C was obtained and then added to the aforementioned culture medium, - the mass percentage of oil C expressed in relation to the mass of said culture medium was 0.001% (i.e. 0.000533% of 13-HOD, if we consider the very small mass of unsaponifiables present in said oil C as negligible and taking into account that oil C contained essentially free fatty acids, of which 13-HOD had a mass content of 53.3%).

[0153] After 24 hours of treatment of dermal papilla cells with C oil at a mass concentration of 0.001%, the cells were washed and collected. RNA extraction was then performed using Trizol® and chloroform. After quantification, the RNA was reverse-transcribed into cDNA to assess VEGF gene expression. Ct values ​​were normalized to those of the reference gene GAPDH.

[0154] Test 4B:

[0155] Oil C was diluted in DMSO to obtain a stock solution of said oil C having a concentration of said oil A of 10 mg / mL.

[0156] The stock solution of oil C was appropriately diluted in DMSO such that: - that a diluted solution of said oil C was obtained and then added to the aforementioned culture medium, - the mass percentage of oil C expressed in relation to the mass of said culture medium was 0.002% (i.e. 0.001066% of 13-HOD if we consider the very small mass of unsaponifiables present in said oil C as negligible and taking into account that oil C contained essentially free fatty acids, of which 13-HOD had a mass content of 53.3%; which corresponded to a concentration of 36 pmol / L of 13-HOD).

[0157] After 24 hours of treatment of dermal papilla cells with C oil at a mass concentration of 0.002%, the cells were washed and collected. RNA extraction was then performed using Trizol® and chloroform. After quantification, the RNA was reverse-transcribed into cDNA to assess VEGF gene expression. Ct values ​​were normalized to those of the reference gene GAPDH.

[0158] Test 4 C:

[0159] Minoxidil is a compound whose chemical structure (4) is as follows:

[0160] [Chem.4] çP .NHV - ■M (4)

[0161] Minoxidil is a vasodilator and antihypertensive drug initially used to treat high blood pressure. It has been observed that one of the side effects of this drug is increased hair growth. Therefore, it is known that minoxidil can be applied to the scalp to slow hair loss and even promote regrowth. Thus, due to its recognized application in stimulating hair growth, minoxidil constitutes a comparable compound in the present invention.

[0162] Minoxidil was appropriately diluted in the aforementioned culture medium such that the concentration of minoxidil in said culture medium was 100 pmol / L.

[0163] After 24 hours of treatment of dermal papilla cells with minoxidil at a concentration of 100 pmol / L, the cells were washed and collected. RNA extraction was then performed using Trizol® and chloroform. After quantification, the RNA was reverse-transcribed into cDNA to assess VEGF gene expression. Ct values ​​were normalized to those of the reference gene GAPDH.

[0164] Test Control 4:

[0165] Furthermore, a Control Test 4 was performed by adding no active ingredient to the culture medium in which the dermal papilla cells were cultured. After 24 hours of culture of said dermal papilla cells, the cells were washed and collected. Then, RNA extraction was performed using Trizol® and chloroform. After quantification, the RNA was reverse-transcribed into cDNA to evaluate VEGF gene expression. Ct values ​​were normalized to those of the reference gene GAPDH.

[0166] Figure 4 is a graph representing VEGF gene expression in dermal papilla cells during assays 4A to 4C, with VEGF gene expression expressed as a percentage relative to VEGF gene expression obtained during Control Assay 4 and normalized to 100%.

[0167] As shown in the graph in [Fig. 4], in trial 4B, oil C containing 13-HOD significantly stimulated VEGF gene expression (+20%). Minoxidil at a concentration of 100 pmol / L significantly stimulated VEGF expression in dermal papilla cells by 30%. The difference observed in trials 4B and 4C between the effect of minoxidil and the effect of oil C containing 13-HOD is not significant. The effect of these two compounds is therefore similar at a concentration of 13-HOD three times lower (i.e., 36 pmol / L versus 100 pmol / L).

[0168] 5 — series of experiments: Effect of oil B on follicle growth hairy in culture:

[0169] The following 5A and Control 5 tests were carried out.

[0170] For these 5A and Control 5 tests, the culture medium was the SFM of keratinocytes marketed by THERMO FISHER SCIENTIFIC and which was placed in a humid atmosphere containing 5% CO2 at 37°C.

[0171] Test 5A:

[0172] Oil B was diluted in DMSO to obtain a stock solution of said oil B having a concentration of said oil B of 10 mg / mL.

[0173] The stock solution of oil B was appropriately diluted in DMSO such that: - that a diluted solution of said oil B was obtained and then added to the culture medium as detailed in previous experiments, - the mass percentage of oil B expressed in relation to the mass of said culture medium was 0.0005% (i.e. 0.0002345% of 13-HOD, if we consider the very small mass of unsaponifiables present in said oil B as negligible and taking into account that oil B contained essentially free fatty acids, of which 13-HOD had a mass content of 46.9%).

[0174] Hair follicles were extracted from surgical residues and cultured in the culture medium which comprised 0.0005% of oil B.

[0175] At 3 and 7 days after the start of the experiment, half of the culture medium containing 0.0005% oil B was replaced. The hair follicles were cultured for a total of 10 days. Their lengths were measured after 0, 1, 3, 7, and 10 days of the experiment by microscopy image analysis.

[0176] Test 5 Control:

[0177] In addition, a Control Trial 5 was carried out by adding no active ingredient to the culture medium in which the hair follicles were grown. As in Trial 5A, half of the culture medium was replaced at 3 and 7 days after the start of the experiment. The follicles were grown for a total duration of 10 days. Their lengths were measured after 0, 1, 3, 7 and 10 days of experimentation, by microscopy image analysis.

[0178] Figure 5 is a graph of the change in hair follicle length in Test 5A and Control Test 5 over time. More specifically, this length is expressed as a percentage relative to the hair follicle length in Control Test 5 at the beginning of the experiment (i.e., Day 0) and normalized to 100%.

[0179] In view of the shape of the curves of trial 5A and trial Control 5, it can be noted that oil B containing 13-HOD significantly stimulates the growth of hair follicles in culture from 7 days up to 10 days of culture (increase of 14% and 16% respectively after 7 days and 10 days of culture compared to trial Control 5).

[0180] 6 — series of experiments: Effect of C oil on hair growth on skin expiators:

[0181] The following tests 6A, 6B and Control 6 were carried out.

[0182] For these tests 6A, 6B and Control 6, the culture medium was a culture medium suitable for the growth of hair on skin expiants and which was placed in a humid atmosphere containing 5% CO2 at 37°C.

[0183] Tests 6A and 6B:

[0184] During tests 6A and 6B, the following cosmetic composition was used. The list of its constituents and their mass percentages expressed relative to the total mass of said composition are detailed in Table 1 below. [Tables 1] Constituents Mass Percentages water 72.55 coco-caprylate / caprate and tocopherol 20.00 arachidyl alcohol, behenyl alcohol, arachidyl glucoside 3.00 methylpropanediol, caprylyl glycol, phenylpropanol 2.00 propanediol 1.50 polyacrylate crosspolymer-6 0.30 water, citric acid 0.25 xanthan gum 0.10 potassium sorbate 0.10 Tested active ingredient 0.1 sodium benzoate 0.10

[0185] For test 6A, the active ingredient tested was oil C and for test 6B, the active ingredient tested was castor oil.

[0186] Skin expiants (77-year-old female donor) with at least 3 hair follicles were cultured in the culture medium.

[0187] For tests 6A and 6B, the cosmetic composition detailed above was applied daily for 5 days to these cultured skin explants. Specifically, 2 mg of said composition was applied per cm² of skin explant.

[0188] Hair length was measured after 2 and 5 days of such treatment.

[0189] Test Control 6:

[0190] For control trial 6, skin expiants (77-year-old female donor) with at least 3 hair follicles were cultured in the culture medium.

[0191] No composition was applied to these skin expiants.

[0192] Fig. 6 is a graph which represents, for tests 6A, 6B and Control 6, the relative hair growth between days 2 and 5 of culture, expressed as a percentage relative to hair length on day 2.

[0193] As shown in [Fig. 6], the relative hair growth measured on the untreated expellents is 102% (i.e., Control 6 trial). This rate is 125% for the expellents in Test 6A, i.e., the expellents treated with oil C which contains 13-HOD, and is significantly higher than that of the expellents in Control 6 trial.

[0194] The hair growth rate in trial 6A is higher than that in trial 6B, namely the trial carried out with castor oil (125% versus 113%). Oil C has a beneficial effect on hair growth and is greater than that of castor oil.

[0195] Thus, at equivalent concentration, oil C containing 13-HOD has a greater stimulatory effect on hair growth than castor oil.

[0196] 7 — series of experiments: Effect of oil C, implemented in cosmetic compositions that have been rinsed _ on the porosity of the hair cuticle;

[0197] The cuticle is a waterproof, scale-like protection that covers the hair shaft.

[0198] The following tests 7a to 7D and Control 7 were carried out.

[0199] For each of these trials, 3 strands of hair from a Caucasian donor were used.

[0200] The hair strands in tests 7A to 7D were exposed to heat stress at 95°C for one hour. The strands in Control Test 7 were not exposed to such heat stress.

[0201] Tests 7A and 7B:

[0202] During tests 7A and 7B, the following cosmetic compositions 1 and 2 were used respectively. The list of their constituents and their mass percentages expressed relative to the total mass of the composition concerned are detailed in Table 2 below. [Tables 2] Constituents Mass Percentage Composition 1 Composition 2 Water 65.755 65.705 Water, Disodium Cocoyl Glutamate, Sodium Cocoyl Alaninate 20.00 20.00 Water, Sodium Cocoamphoacetate 8.00 8.00 Caprylyl / Capryl Glucoside, Water 3.00 3.00 Citric Acid, Water 1.97 1.97 Sphingomonas Ferment Extract 0.50 0.50 1,2-Heptanediol 0.50 0.50 Guar Hydroxypropyltrimonium Chloride, Water 0.10 0.10 Sodium Dihydroacetate 0.10 0.10 Oil C 0.05 0.10 Sodium Phytate 0.025 0.025

[0203] For tests 7A and 7B, compositions 1 and 2 were respectively applied to damp hair strands for 10 minutes. Then, these hair strands were washed three times with ultrapure water. These application steps of compositions 1 and 2 and the three washes were repeated twice more before a final air-drying step.

[0204] The hair strands were then soaked in a fluorophore solution (namely a fluorescein solution) and subsequently cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0205] Test 7C:

[0206] No composition was applied to the hair strands in test 7C. The hair strands were washed three times with ultrapure water and then air-dried. They were then soaked in a fluorescein solution and cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0207] 7D Test:

[0208] During the 7D trial, a cosmetic composition referred to as a "placebo" was used. The list of its constituents and their mass percentages expressed relative to the total mass of the cosmetic composition referred to as a "placebo" are detailed in Table 3 below. [Tables 3] Constituents (percentage by mass): water 65.805, water, disodium cocoyl glutamate, sodium cocoyl alaninate 20.00, water, sodium cocoamphoacetate 8.00, caprylyl / capryl glucoside, water 3.00, citric acid, water 1.97, sphingomonas ferment extract 0.50, 1,2-heptanediol 0.50, guar chloride, hydroxypropyltrimonium, water 0.10, sodium dihydroacetate 0.10, sodium phytate 0.025

[0209] For test 7D, the so-called "placebo" composition was applied to damp hair strands for 10 minutes. Then, these hair strands were washed three times with ultrapure water. These steps of applying the so-called "placebo" composition and washing three times were repeated twice more before a final air-drying step.

[0210] The hair strands were then soaked in a fluorescein solution and subsequently cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0211] Test Control 7:

[0212] The hair strands in Control Test 7 were not subjected to heat treatment. Furthermore, no cosmetic composition was applied to them. The Strands of hair were washed three times in ultrapure water and then air-dried. Next, they were soaked in a fluorescein solution and then cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0213] Fig. 7 is a graph which represents, for tests 7A to 7D and Control 7, the diffusion of the fluorophore within the fibers of the hair strands, said diffusion of the fluorophore being the penetration distance of the fluorophore within said fibers expressed as a percentage relative to the diameter of said fibers.

[0214] In the absence of thermal stress, the hair strands in Test Control 7 have fibers whose structural integrity prevents the diffusion of the fluorophore. The percentage of fluorophore diffusion is 10.78%.

[0215] After heat stress, the fibers of the hair strands became porous (in other words, they are no longer intact) and the diffusion of the fluorophore increased by 88%.

[0216] The higher the diffusion of the fluorophore, the more porous the fibers of the hair strands have become.

[0217] That is why for test 7C, the percentage of diffusion of the fluorophore is 20.25%.

[0218] Treating hair strands with a cosmetic composition including oil C containing 13-HOD (i.e., tests 7A and 7B) restored the integrity of the hair strand fibers. Indeed, the fluorophore diffusion percentages were 11.88% and 10.31% for tests 7A and 7B, respectively.

[0219] Treating the hair strands with a so-called "placebo" composition did not restore the integrity of the hair strand fibers to the same extent. Indeed, the fluorophore diffusion percentage for the 7D trial was 14.15%.

[0220] Thus, treating hair strands with a cosmetic composition including oil C containing 13-HOD restored the integrity of the hair strand fibers with greater efficacy than the so-called "placebo" composition. Indeed, the diffusion of the fluorophore decreased by 88% and 105% in trials 7A and 7B respectively, and by only 64% in trial 7D (with the so-called "placebo" composition).

[0221] This 7th series of experiments demonstrates that 13-HOD is effective in repairing the hair fiber.

[0222] 8 — series of experiments: Effect of oil C, implemented in Leave-on cosmetic compositions, on the porosity of the hair cuticle:

[0223] The following tests 8a to 8C and Control 8 were carried out.

[0224] For each of these trials, 3 strands of hair from a Caucasian donor were used.

[0225] The hair strands in tests 8A to 8C were exposed to heat stress at 95°C for one hour. The strands in Control Test 8 were not exposed to such heat stress.

[0226] Test 8A j.

[0227] During test 8A, the following cosmetic composition was used. The list of their constituents and their mass percentages expressed relative to the total mass of the composition concerned are detailed in Table 4 below. [Tables 4] Constituents Mass Percentages Water 72.60 Oil C 0.05 Methylpropanediol, Caprylyl Glycol, Phenyl Ipropanol 2.00 Xanthan Gum 0.10 Polyacrylate Crosspolymer-6 0.30 Coco-Caprylate / Caprate and Tocopherol 20.00 Arachidyl Alcohol, Behenyl Alcohol, Arachidyl Glucoside 3.00 Propanediol 1.50 Potassium Sorbate 0.10 Sodium Benzoate 0.10 Water, Citric Acid 0.25

[0228] The composition was applied to dry hair strands. Then, the hair strands were directly air-dried. In other words, the hair strands were not rinsed.

[0229] The hair strands were then soaked in a fluorophore solution (namely a fluorescein solution) and subsequently cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0230] Test 8B:

[0231] During trial 8B, a so-called "placebo" cosmetic composition was used. The list of its constituents and their mass percentages expressed relative to The total mass of the cosmetic composition known as "placebo" is detailed in Table 5 below. [Tables 5] Constituents (mass percentages): water 72.65, methylpropanediol, caprylyl glycol, phenylpropanol 2.00, xanthan gum 0.10, polyacrylate crosspolymer-6 0.30, coco-caprylate / caprate and tocopherol 20.00, arachidyl alcohol, behenyl alcohol, arachidyl glucoside 3.00, propanediol 1.50, potassium sorbate 0.10, sodium benzoate 0.10, water, citric acid 0.25

[0232] The so-called “placebo” composition was applied to dry hair strands. Then, the hair strands were air-dried. In other words, the hair strands were not rinsed.

[0233] The hair strands were then soaked in a fluorescein solution and cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0234] Test 8C:

[0235] No composition was applied to the hair strands in test 8C. The hair strands were washed three times with ultrapure water and then air-dried. They were then soaked in a fluorescein solution and cryopreserved. Cross-sections were prepared. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0236] Test Control 8 days.

[0237] The hair strands in Control 8 were not subjected to heat treatment. Furthermore, no cosmetic composition was applied to them. The hair strands were washed three times with ultrapure water and then air-dried. They were then soaked in a fluorescein solution and subsequently cryopreserved. Cross-sections were obtained. The fluorescent signal was visualized by microscopy and quantified by image analysis.

[0238] Fig. 8 is a graph which represents, for tests 8A to 8C and Control 8, the diffusion of the fluorophore within the fibers of the hair strands, said diffusion of the fluorophore being the penetration distance of the fluorophore within said fibers expressed as a percentage relative to the diameter of said fibers.

[0239] In the absence of thermal stress, the hair strands in Test Control 8 have fibers whose structural integrity prevents the diffusion of the fluorophore. The percentage of fluorophore diffusion is 10.78%.

[0240] After thermal stress, the fibers of the hair strands became porous (in other words, they are no longer intact) and the diffusion of the fluorophore increased by 88%.

[0241] The higher the diffusion of the fluorophore, the more porous the fibers of the hair strands have become.

[0242] That is why for test 8C, the percentage of diffusion of the fluorophore is 20.25%.

[0243] Treating hair strands with a cosmetic composition comprising oil C containing 13-HOD (i.e., test 8A) restored the integrity of the hair strand fibers. Indeed, the fluorophore diffusion rate was 11.53%.

[0244] Treating the hair strands with a so-called "placebo" composition did not restore the integrity of the hair strand fibers to the same extent. Indeed, the percentage of fluorophore diffusion for test 8B was 13.97%.

[0245] Thus, treating hair strands with a cosmetic composition including oil C containing 13-HOD restored the integrity of the hair strand fibers with greater efficacy than the so-called "placebo" composition. Indeed, the diffusion of the fluorophore decreased by 92% in Trial 8A and by only 66% in Trial 8B (with the so-called "placebo" composition).

[0246] This 8th series of experiments demonstrates that 13-HOD is effective in repairing the hair fiber.

[0247] Tables 6 to 9 below detail examples of cosmetic compositions according to the invention by listing their constituents and the associated mass percentages, which are expressed relative to the mass of the cosmetic composition in question. The constituents are listed with their INCI nomenclature names (INCI being the English abbreviation for "International Nomenclature of Cosmetic Ingredients").

[0248] In all the tables below, the abbreviation "QSP 100" means "quantity sufficient for 100%". This is the mass percentage of water so that the sum mass percentages of all constituents of the cosmetic composition reach 100%.

[0249] All the cosmetic compositions detailed below included C oil.

[0250] Anti-hair loss serum composition according to invention j. [Tableauxô] INCI Name of Constituents Mass Percentage (%) WATER QSP 100 ALCOHOL 20 POLYGLYCERYL-4 CAPRATE 3 POLYGLYCERYL-6 CAPRYL ATE 3 GLYCERIN 1 FRAGRANCE 0.2 OIL C 5 to 0.0005 PISUM SATIVUM (PEA) EXTRACT 0.005 SALVIA HISPANICA SEED EXTRACT 0.005

[0251] Composition of anti-hair loss shampoo according to the invention [Tables?] INCI name of constituents Mass percentage (%) WATER QSP 100 SODIUM LAUROYL SARCOSINA TE 9 SODIUM COCOAMPHOACETATE 5 POLYGLYCERYL-4 CAPRATE 2 POLYGLYCERYL-6 CAPRYLATE 2 OIL C 5 to 0.0005 FRAGRANCE 1 CITRIC ACID QSP pH 5 to 6 SPHINGOMONAS FERMENT EXT RACT 0.3

[0252]

[0253] The abbreviation "QSP pH 5 to 6" is the abbreviation for quantity sufficient for pH of 5 to 6. It is the mass percentage of citric acid so that the pH of the cosmetic composition is between 5 and 6.

[0254] Composition of hair mask according to invention j. [Tables 8] INCI Name of Constituents Mass Percentage (%) WATER QSP 100 BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT 10 CETEARYL ALCOHOL 5 ETHYLHEXYL PELARGONATE 5 CETYL ALCOHOL 4 HYDROGENATED VEGETABLE OIL 4 C15-19 ALKANE 3 HYDROGENATED POLYFARNESEN E2 VITIS VINIFERA (GRAPE) SEED OIL 1 CAPRYLYL / CAPRYL GLUCOSIDE 1 PARFUM 0.7 ARGININE QS pH 5-6 CAESALPINIA SPINOSA GUM 0.5 CHONDRUS CRISPUS (CARRAGEE NAN) POWDER 0.5 SODIUM BENZOATE 0.5 GLYCERIN 0.4 POTASSIUM SORBATE 0.2 HELIANTHUS ANNUUS (SUNFLOW ER) SEED OIL 0.2 SODIUM CHLORIDE 0.2 POLYGLYCERYL-10 LAURATE 0.2 CITRIC ACID QSP pH 5 to 6 POTASSIUM CETYL PHOSPHATE 0.2

[0255]

[0256] Composition of nourishing and repairing shampoo according to invention j. [Tables 9] INCI Name of Constituents Mass Percentage (%) WATER QSP 100 SODIUM LAUROYL SARCOSINATE 10 SODIUM COCOAMPHOACETATE 5 OIL C 5 to 0.0005 BUTYLENE GLYCOL 2 CAPRYLYL / CAPRYL GLUCOSIDE 2 PARFUM 0.6 GLYCERIN 0.5 CARBOMER 0.3 SPHINGOMONAS FERMENT EXTRACT 0.3 GUAR HYDROXYPROPYLTRIMONIUM CH IROIDE 0.3 CITRIC ACID QS pH 5 to 6 SODIUM DEHYDROACETATE 0.1 VITIS VINIFERA (GRAPE) SEED OIL 0.1

Claims

Demands

1. Cosmetic composition, characterized in that it comprises as an active ingredient 13-hydroxy-9(Z)-octadecenoic acid (hereinafter abbreviated 13-HOD).

2. Cosmetic composition according to claim 1, characterized in that it comprises at least one modified vegetable oil containing 13-HOD.

3. Cosmetic composition according to claim 2, characterized in that said modified vegetable oil comprises, in mass percentages expressed in relation to the total mass of free fatty acids contained in said modified vegetable oil, at least 10%, preferably at least 20% and even more preferably at least 40%, of 13-HOD.

4. Cosmetic composition according to claim 2 or 3, characterized in that said vegetable oil is selected from the group consisting of grape seed, safflower, borage, peanut, wheat germ, maize, sunflower, blackberry, nigella, evening primrose, pumpkin seed, hemp, cotton, walnut, soybean, argan and rapeseed oil, taken alone or in mixtures thereof.

5. Cosmetic composition according to claim 4, characterized in that said vegetable oil is a grape seed oil.

6. Cosmetic composition according to any one of claims 1 to 5, characterized in that it comprises, in mass percentages expressed in relation to the total mass of said cosmetic composition, between 0.0001% and 1%, preferably between 0.001% and 0.1%, of 13-HOD.

7. Cosmetic composition according to any one of claims 2 to 6, characterized in that the mass percentage of said modified vegetable oil, expressed in relation to the total mass of said cosmetic composition, is between 0.0005% and 5%, preferably between 0.005% and 0.5%.

8. A non-therapeutic cosmetic treatment method for stimulating hair growth, characterized in that it comprises a step of applying the cosmetic composition according to any one of claims 1 to 7 to a determined hairy area.

9. A non-therapeutic cosmetic treatment method according to claim 8, characterized in that the determined hair area is all or part of the scalp, chin, eyebrows or free edges of the eyelids on which the eyelashes are implanted.

10. A non-therapeutic cosmetic treatment method for repairing hair fibers, characterized in that it comprises a step of applying the cosmetic composition according to any one of claims 1 to 7 to all or part of the scalp.

11. Non-therapeutic cosmetic use of 13-HOD to stimulate hair growth.

12. Non-therapeutic cosmetic use of 13-HOD to repair hair fiber.

Citation Information

Patent Citations

  • PROCEDURE FOR THE PRODUCTION OF NATURAL DODECALACTONES AND DECALACTONES BY BIOTRANSFORMATION OF VEGETABLE OILS

    IT201900015713A1

  • Method of producing 13-hydroxy-9(Z)-octadecenoic acid

    US11499171B2

  • Natural composition for hair growth stimulation and hair loss prevention and treatment without preservatives

    WO2021209437A1

  • Natural composition for hair growth stimulation and hair loss prevention and treatment

    WO2021209442A1

  • Method for producing 13-hydroxy-9(z)-octadecenoic acid

    EP3778910A1